Invictus MD Strategies (Invictus MD Strategies) EV-to-EBIT : 0.00 (As of May. 11, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Invictus MD Strategies EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Invictus MD Strategies's Enterprise Value is $0.00 Mil. Invictus MD Strategies's EBIT for the trailing twelve months (TTM) ended in Oct. 2019 was $-26.80 Mil. Therefore, Invictus MD Strategies's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for Invictus MD Strategies's EV-to-EBIT or its related term are showing as below:

IVITF's EV-to-EBIT is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 17.95
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Invictus MD Strategies's Enterprise Value for the quarter that ended in Oct. 2019 was $21.80 Mil. Invictus MD Strategies's EBIT for the trailing twelve months (TTM) ended in Oct. 2019 was $-26.80 Mil. Invictus MD Strategies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Oct. 2019 was -122.94%.

Invictus MD Strategies EV-to-EBIT Historical Data

The historical data trend for Invictus MD Strategies's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invictus MD Strategies EV-to-EBIT Chart

Invictus MD Strategies Annual Data

Trend

Jan15

Jan16

Jan17

Jan18

Jan19

EV-to-EBIT

-14.98

35.65

-7.31

-7.22

-4.03

Invictus MD Strategies Quarterly Data
	Jan15	Apr15	Jul15	Oct15	Jan16	Apr16	Jul16	Oct16	Jan17	Apr17	Jul17	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19
EV-to-EBIT	Get a 7-Day Free Trial															-4.15	-4.03	-2.70	-1.48	-0.79

Competitive Comparison of Invictus MD Strategies's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Invictus MD Strategies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invictus MD Strategies's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Invictus MD Strategies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Invictus MD Strategies's EV-to-EBIT falls into.

Invictus MD Strategies EV-to-EBIT Calculation

Invictus MD Strategies's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	0.000	/	-26.801
	=	0.00

Invictus MD Strategies's current Enterprise Value is $0.00 Mil.
Invictus MD Strategies's EBIT for the trailing twelve months (TTM) ended in Oct. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-26.80 Mil.

Invictus MD Strategies (OTCPK:IVITF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Invictus MD Strategies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Oct. 2019 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Oct. 2019 )	=	EBIT	/	Enterprise Value (Q: Oct. 2019 )
	=	-26.801	/	21.80013
	=	-122.94 %

Invictus MD Strategies's Enterprise Value for the quarter that ended in Oct. 2019 was $21.80 Mil.
Invictus MD Strategies's EBIT for the trailing twelve months (TTM) ended in Oct. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-26.80 Mil.

Invictus MD Strategies EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Invictus MD Strategies's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Invictus MD Strategies (Invictus MD Strategies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Invictus MD Strategies Corp (OTCPK:IVITF) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

595 Burrard Street, 16th floor, Vancouver, BC, CAN, V7X 1J1

Website

http://www.invictus-md.com

Invictus MD Strategies Corp is a cannabis company with a focus on the Canadian cannabis space, offering a selection of products under a wide range of cannabinoid profiles that fit the demand of the company's medical clients and retail customers. Its wholly-owned subsidiary's Phase I and Phase II facilities are in full production. The company's 50% owned subsidiary has completed its Phase II expansion and received its amended license from Health Canada. Another of its wholly owned subsidiary, connects medical clients to physicians for medical cannabis.